AI Cancer Diagnostics Firm Ibex Granted FDA Breakthrough Device Designation
News BriefsTech & Innovation
Pathologists review a cancer alert on Ibex’s AI solution. Courtesy
Israeli AI-powered cancer diagnostics company Ibex Medical Analytics announced on Wednesday that it was granted Breakthrough Device Designation by the US Food and Drug Administration (FDA) for its Galen platform that helps pathologists detect and grade cancer in biopsies.
Ibex’s Galen Prostate and Galen Breast are the first AI-powered cancer diagnostics solutions in routine clinical use in pathology and are deployed in labs worldwide. The Galen platform offers the Ibex First Read and the Ibex Second Read, applications that analyze cases prior to human pathologist review, enabling case prioritization, and in parallel with human pathologist review to identify any discrepancies, respectively. The Second Read system for breast and prostate biopsies have been used at the Pathology Institute of Maccabi Healt
Startup's existing investors and new ones participate in funding round; app helps people with diabetes and other metabolic diseases eat best-suited foods
Israeli precision medicine co DayTwo raises $37m
DayTwo uses AI, the sequencing of the gut microbiome and other clinical measures to create precision nutrition-based food prescriptions to balance blood sugar levels after meals.
Israeli precision medicine company DayTwo has raised $37 million to continue development of technologies and solutions designed to improve the health of people with diabetes and other metabolic diseases. DayTwo’s existing investors participated in this latest financing round including aMoon of Marius Nacht and Dr. Yair Schindel, 10D of Yahal Zilka, and Cathay Innovation Ventures. They were joined by new investors, including Poalim Capital Markets, La’maison Fund and Micron Ventures. This round brings the total amount invested in DayTwo to $85 million.
Digital health incubator eHealth Ventures raising $30m
The funding being raised by the incubator will enable it to act as a mini venture capital fund, while it continues to receive benefits from the Israel Innovation Authority.
eHealth Ventures, part of the national network of tech incubators supported by the Israel Innovation Authority, is raising $30 million. The funding being raised by the incubator, which specializes in digital health, will enable it to act as a mini venture capital fund, while it continues to receive benefits from the Israel Innovation Authority. eHealth Ventures CEO and managing partner Talor Sax told Globes that most of the money has been pledged and the first closing is expected before the end of next month. The incubator has also announced a strategic partnership with the Mayo Clinic in the US.